Retatrutide Availability Tracker
Patient interest in retatrutide is enormous, but access remains limited as the drug progresses through clinical development. This tracker provides current availability information and projected timelines for broader access (Jastreboff et al., NEJM 2023).
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Be cautious of unregulated sources claiming to sell retatrutide.
Current Availability Status (April 2026)
| Access Method | Status | Details |
|---|---|---|
| FDA-approved brand | Not available | Awaiting Phase 3 completion and FDA review |
| Clinical trials | Limited enrollment | TRIUMPH program sites; check ClinicalTrials.gov |
| Compounding pharmacies | Emerging | Some compounding pharmacies beginning to offer |
| Research peptide sites | Not recommended | Unregulated; safety and purity not guaranteed |
Clinical Trial Access
The TRIUMPH Phase 3 program is conducted at research sites across the United States and internationally. To explore clinical trial participation:
- Visit ClinicalTrials.gov and search "retatrutide" or "LY3437943"
- Filter by recruiting status and your location
- Contact the listed study coordinator for eligibility screening
- Clinical trial benefits: free medication, regular medical monitoring, contributing to science
- Clinical trial limitations: randomization (may receive placebo), visit requirements, protocol restrictions
Compounding Pharmacy Access
Some compounding pharmacies have begun offering retatrutide. Key considerations include ensuring the pharmacy is licensed and accredited (PCAB accreditation is the gold standard), requiring a valid prescription from a licensed provider, verifying the pharmacy performs third-party purity testing, and understanding that compounded medications are not FDA-approved products.
Warning: Unregulated Sources
Research chemical websites and overseas suppliers selling "retatrutide" should be avoided. These products are not manufactured to pharmaceutical standards, may contain incorrect doses or contaminants, carry risks of infection and immune reactions, have no medical oversight or quality control, and are illegal to sell for human use in the United States. The health risks of using unverified peptides far outweigh any potential benefit.
Projected Availability Timeline
| Timeframe | Expected Availability |
|---|---|
| Now (April 2026) | Clinical trials; select compounding pharmacies |
| Late 2026 - Early 2027 | Phase 3 results; expanded compounding access possible |
| 2027 | FDA submission expected; pre-approval access programs possible |
| Late 2027 - 2028 | Potential FDA approval and commercial launch |
What to Do While Waiting
If you are interested in retatrutide but it is not yet accessible, do not wait to address obesity. Effective GLP-1 medications are available now, and starting treatment sooner produces better long-term outcomes. You can switch to retatrutide when it becomes available.
Start GLP-1 Treatment Today
Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month), available now with full medical support. Begin your weight loss journey while the next generation of treatments develops. Learn how Trimi works.
Frequently Asked Questions
Can I get retatrutide from my doctor today?
Not through a standard prescription. Retatrutide is not FDA-approved and cannot be dispensed by retail pharmacies. Access is currently limited to clinical trials and select compounding pharmacies.
Is it safe to buy retatrutide online?
Only from licensed, accredited compounding pharmacies with a valid prescription. Never purchase from research chemical websites, overseas suppliers, or unverified online sources.
Should I wait for retatrutide or start semaglutide/tirzepatide now?
Start treatment now. Obesity worsens over time, and delaying treatment has real health consequences. Semaglutide and tirzepatide are proven, effective medications. You can transition to retatrutide when it becomes available.
Will Trimi offer retatrutide?
Trimi is committed to offering the most effective GLP-1 treatments at accessible prices. As retatrutide becomes available through legitimate channels, Trimi plans to evaluate adding it to our treatment options.